OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 92. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
COVID-19 and its implications for thrombosis and anticoagulation	1722
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1046
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	955
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	887
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	875
Platelet gene expression and function in patients with COVID-19	718
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	568
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	534
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	520
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial	470
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	461
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	428
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	318
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	298
Venous thromboembolism in cancer patients: a population-based cohort study	286
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	284
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	277
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report	275
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients	244
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	239
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	238
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure	208
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	200
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era	197
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	194

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	189
Postdischarge thrombosis and hemorrhage in patients with COVID-19	181
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	176
Glucose-6-phosphate dehydrogenase deficiency	173
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial	169
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	162
Antibody-induced procoagulant platelets in severe COVID-19 infection	158
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI	157
NPM1-mutated acute myeloid leukemia: from bench to bedside	157
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	157
Postdischarge venous thromboembolism following hospital admission with COVID-19	155
Therapeutic options in VEXAS syndrome: insights from a retrospective series	151
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	150
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	148
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	146
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	145
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	141
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	139
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	138
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	136
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	136
Management of AL amyloidosis in 2020	135
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	134
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	134
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	131
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	127
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	121
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	121
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	121
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	120
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	120
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	119
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	119
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	119
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	115
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	115
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Developmental trajectory of prehematopoietic stem cell formation from endothelium	114
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	114
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	114
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	112
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	112
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	112
Diamond-Blackfan anemia	109
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	109
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	109
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	106
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	105
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	105

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	105
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	102
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	101
Redefining outcomes in immune TTP: an international working group consensus report	99
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	98
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	98
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	98
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	98
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	97
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	95
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	95
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	94
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation	94
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	94
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	93
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR	93
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	92
How I treat relapsed acute lymphoblastic leukemia in the pediatric population	92
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	92
Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor	92